InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,514.56
(
0.58%
)
US TECH 100
19,421.99
(
0.82%
)
Dow Jones
39,418.66
(
0.65%
)
Brent Oil
84.87
(
-0.64%
)
Bitcoin
60,763.57
(
-1.38%
)
Post# of 252412
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119944
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: tika1 post# 222990

Wednesday, 05/08/2019 10:56:17 AM

Wednesday, May 08, 2019 10:56:17 AM

Post# of 252412
PTLA’s Bevyxxa sales continue to be negligible:

https://www.globenewswire.com/news-release/2019/05/08/1819333/0/en/Portola-Pharmaceuticals-Reports-First-Quarter-2019-Financial-Results-and-Provides-Corporate-Update.html

1Q19 Bevyxxa sales were $77,000 (not a typo).

Andexxa sales are not exactly on fire either: 1Q19 sales were $20.3M.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up